SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company's common shares are now eligible to be included in the NASDAQ Global Market and will begin trading there under the same symbol "PARD" effective Monday, October 1, 2007.
"Qualifying for listing on the NASDAQ Global Market represents an important milestone for Poniard and provides us with greater visibility in the global financial markets and broadens our exposure to new investors," said Caroline Loewy, chief financial officer of Poniard. "This is an important step in our continued growth and demonstrates our ability to meet the higher standards required by the NASDAQ Global Market."
NASDAQ-listed companies are classified under three listing tiers -- NASDAQ Global Select Market, NASDAQ Global Market and NASDAQ Capital Market. Poniard has been listed on the NASDAQ Capital Market. All three market tiers maintain rigorous listing and corporate governance standards. For additional information about the NASDAQ Global Market, please visit http://www.nasdaq.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the discovery, development and commercialization of innovative oncology
products to impact the lives of people with cancer. Picoplatin, the
Company's lead product candidate, is a new generation platinum therapy with
an improved safety profile. Picoplatin is designed to overcome and prevent
platinum resistance associated with chemotherapy in solid tumors.
Intravenous picoplatin is currently being studied in c
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved